Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with orphan diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. We seek best-in-class leaders with scientific, medical and commercial expertise in the therapeutic areas in which we participate. By sharing a collective passion for making a difference in the lives of patients we serve, our unique company culture thrives through the principles of ethical decision making, open communication and collaboration. Zogenix was founded in 2006 and has offices in California and the United Kingdom. Zogenix International, Ltd. is a wholly owned subsidiary of Zogenix.
Emeryville, US
Size (employees)
67 (est)+9%
Zogenix was founded in 2006 and is headquartered in Emeryville, US

Zogenix Office Locations

Zogenix has offices in Emeryville, San Diego and Maidenhead
Emeryville, US (HQ)
455 5858 Horton St
Maidenhead, GB
San Diego, US
650 12400 High Bluff Dr

Zogenix Data and Metrics

Zogenix Financial Metrics

Zogenix's revenue was reported to be $28.9 m in FY, 2016 which is a 6% increase from the previous period.

Revenue (FY, 2016)

28.9 m

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(69.7 m)

EBIT (FY, 2016)

(72.7 m)

Market capitalization (21-Jul-2017)

337.5 m

Cash (31-Dec-2016)

91.6 m
Zogenix's current market capitalization is $337.5 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


33 m40.5 m27.2 m28.9 m

Revenue growth, %


Cost of goods sold

21.2 m15.8 m

Gross profit

11.8 m24.7 m

Gross profit Margin, %


Operating expense total

86.2 m60.6 m74.9 m101.5 m


(53.2 m)(20 m)(72.7 m)

EBIT margin, %


Interest expense

6.6 m3.1 m3 m2.8 m

Interest income

18 k20 k

Pre tax profit

(80.9 m)(69.6 m)

Income tax expense

(84 k)948 k

Net Income

(80.9 m)8.6 m26.1 m(69.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016


72 m42.2 m155.3 m91.6 m

Accounts Receivable

1.4 m1.4 m


4.3 m13.4 m12 m12 m

Current Assets

92.9 m78 m184.6 m119.9 m


13 m10.6 m9.3 m1.7 m


6.2 m6.2 m6.2 m

Total Assets

112.5 m202.8 m306 m231.5 m

Accounts Payable

4.6 m8.5 m5.3 m5.3 m

Current Liabilities

58.8 m44.2 m30.1 m20.3 m

Additional Paid-in Capital

428.5 m456.8 m558.3 m566 m

Retained Earnings

(410.2 m)(401.7 m)(375.5 m)(445.2 m)

Total Equity

182.8 m120.8 m

Financial Leverage

1.7 x1.9 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(80.9 m)8.6 m26.1 m(69.7 m)

Depreciation and Amortization

1.8 m1.6 m1.6 m1.4 m

Accounts Receivable

(1 m)(2.2 m)7.5 m7.5 m


(2 m)(9.2 m)(743 k)(743 k)

Accounts Payable

6.1 m5.6 m(14.2 m)(14.2 m)

Cash From Operating Activities

(44.9 m)(80.8 m)(64.6 m)(72.9 m)

Purchases of PP&E

(810 k)(122 k)(308 k)(103 k)

Cash From Investing Activities

(810 k)61 m85.5 m9.9 m

Cash From Financing Activities

76.5 m(10 m)92.2 m(817 k)

Interest Paid

2.5 m12.8 m1.5 m1.5 m
USDY, 2016


465.3 k

Financial Leverage

1.9 x

Zogenix Market Value History

Zogenix Online and Social Media Presence

Zogenix Company Life and Culture

You may also be interested in